or Try an Advanced Search...

    Technical Analysis for CGEN - Compugen Ltd.

    Grade Last Price % Change Price Change
    D 1.75 4.17% 0.07
    CGEN closed up 4.17 percent on Monday, July 1, 2024, on 40 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical CGEN trend table...
    Date Alert Name Type % Chg
    Crossed Above 200 DMA Bullish 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Fell Below 200 DMA Bearish 4.17%
    180 Bearish Setup Bearish Swing Setup 4.17%
    Stochastic Buy Signal Bullish 4.17%
    Older End-of-Day Signals for CGEN ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 6 hours ago
    60 Minute Opening Range Breakout about 9 hours ago
    Up 5% about 9 hours ago
    Gap Up Partially Closed about 10 hours ago
    Gapped Up (Partial) about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    CGEN Chart by TradingView
    Basic chart:

    Profile

    Compugen Ltd. Description

    Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Life Sciences Immunology Autoimmune Disease Antibodies Treatment Of Cancer Monoclonal Antibodies Monoclonal Antibody Antibody Autoimmunity Biomarkers Rheumatoid Arthritis Therapeutic Products Multiple Myeloma Multiple Sclerosis Autoimmune Disorders Immune Disorders Fusion Protein Compugen Monoclonal Antibody Therapy Treatment Of Multiple Sclerosis Antibody Therapy

    Is CGEN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 17 Compugen to Present at Upcoming Antibody Industrial Symposium
    Jun 4 Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
    May 30 Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
    May 22 Earnings Release: Here's Why Analysts Cut Their Compugen Ltd. (NASDAQ:CGEN) Price Target To US$5.00
    May 20 Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript
    May 20 Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
    May 20 Compugen GAAP EPS of -$0.08 beats by $0.03, revenue of $2.56M beats by $1.35M
    May 20 Compugen Reports First Quarter 2024 Results
    May 17 Compugen Q1 2024 Earnings Preview
    May 16 Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
    See more CGEN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.0301
    52 Week Low 0.53
    Average Volume 352,062
    200-Day Moving Average 1.71
    50-Day Moving Average 2.04
    20-Day Moving Average 1.96
    10-Day Moving Average 1.83
    Average True Range 0.13
    RSI (14) 38.27
    ADX 11.41
    +DI 15.58
    -DI 24.01
    Chandelier Exit (Long, 3 ATRs) 2.02
    Chandelier Exit (Short, 3 ATRs) 2.04
    Upper Bollinger Bands 2.26
    Lower Bollinger Band 1.66
    Percent B (%b) 0.15
    BandWidth 30.46
    MACD Line -0.11
    MACD Signal Line -0.08
    MACD Histogram -0.0277
    Fundamentals Value
    Market Cap 154.57 Million
    Num Shares 88.3 Million
    EPS -0.37
    Price-to-Earnings (P/E) Ratio -4.73
    Price-to-Sales 25.20
    Price-to-Book 3.55
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.84
    Resistance 3 (R3) 1.84 1.81 1.83
    Resistance 2 (R2) 1.81 1.79 1.81 1.82
    Resistance 1 (R1) 1.78 1.77 1.80 1.78 1.81
    Pivot Point 1.75 1.75 1.76 1.75 1.75
    Support 1 (S1) 1.72 1.73 1.74 1.72 1.69
    Support 2 (S2) 1.69 1.71 1.69 1.68
    Support 3 (S3) 1.66 1.69 1.68
    Support 4 (S4) 1.66